Akero Therapeutics, Inc.

BIT:1AKRO Stock Report

Market Cap: €3.9b

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Akero Therapeutics Valuation

Is 1AKRO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of 1AKRO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: Insufficient data to calculate 1AKRO's fair value for valuation analysis.

Significantly Below Future Cash Flow Value: Insufficient data to calculate 1AKRO's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 1AKRO?

Key metric: As 1AKRO is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 1AKRO. This is calculated by dividing 1AKRO's market cap by their current book value.
What is 1AKRO's PB Ratio?
PB Ratio4.7x
BookUS$957.64m
Market CapUS$4.49b

Price to Book Ratio vs Peers

How does 1AKRO's PB Ratio compare to its peers?

The above table shows the PB ratio for 1AKRO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average2.5x
PHIL Philogen
2.5x-107.28%€930.5m
ARBS Arterra Bioscience
1.5xn/a€18.9m
HLX Helyx Industries
1x45.39%€21.3m
REC Recordati Industria Chimica e Farmaceutica
5x15.27%€10.3b
1AKRO Akero Therapeutics
4.7x17.31%€4.5b

Price-To-Book vs Peers: 1AKRO is expensive based on its Price-To-Book Ratio (4.7x) compared to the peer average (3.8x).

Historical Price to Book Ratio

Historical Price to Book Ratio compares a stock's price to the book value of it's equity over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Book Ratio vs Industry

How does 1AKRO's PB Ratio compare vs other companies in the European Biotechs Industry?

31 CompaniesPrice / BookEstimated GrowthMarket Cap
1AKRO 4.7xIndustry Avg. 3.0xNo. of Companies31PB01.63.24.86.48+
31 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: 1AKRO is expensive based on its Price-To-Book Ratio (4.7x) compared to the European Biotechs industry average (2.7x).

Price to Book Ratio vs Fair Ratio

What is 1AKRO's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1AKRO PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio4.7x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 1AKRO's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 1AKRO forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
€48.13
0%
3.19%€49.85€46.41n/a5
Jun ’27n/a
€48.13
0%
3.19%€49.85€46.41n/a5
May ’27n/a
€48.13
0%
3.19%€49.85€46.41n/a5
Apr ’27n/a
€48.13
0%
3.19%€49.85€46.41n/a5
Mar ’27n/a
€48.13
0%
3.19%€49.85€46.41n/a5
Feb ’27n/a
€48.13
0%
3.19%€49.85€46.41n/a5
Jan ’27n/a
€48.13
0%
3.19%€49.85€46.41n/a5
Dec ’26€49.01
€48.13
-1.80%
3.19%€49.85€46.41n/a5
Nov ’26€46.94
€48.15
+2.58%
3.19%€49.87€46.43n/a5
Oct ’26€40.86
€65.79
+61.01%
15.32%€92.77€54.47n/a10
Sep ’26€39.59
€65.69
+65.94%
16.12%€93.88€51.68n/a11
Aug ’26€41.06
€65.66
+59.90%
16.90%€93.79€51.63n/a10
Jul ’26€44.52
€65.18
+46.40%
16.90%€93.11€51.25n/a10
Jun ’26€43.34
€67.21
+55.06%
16.90%€96.01€52.85n/a10
May ’26€39.05
€68.28
+74.86%
16.42%€95.87€52.77n/a11
Apr ’26n/a
€71.72
0%
16.42%€100.69€55.43n/a11
Mar ’26n/a
€74.59
0%
16.59%€105.10€57.85n/a11
Feb ’26n/a
€75.51
0%
16.97%€105.15€57.88n/a11
Jan ’26n/a
€45.58
0%
18.51%€61.37€33.05n/a11
Dec ’25n/a
€45.58
0%
18.51%€61.37€33.05€49.0111
Nov ’25n/a
€42.38
0%
18.26%€55.16€27.58€46.9410
Oct ’25n/a
€41.60
0%
18.26%€54.14€27.07€40.8610
Sep ’25n/a
€42.18
0%
18.26%€54.89€27.45€39.5910
Aug ’25n/a
€41.30
0%
16.63%€51.91€27.81€41.069
Jul ’25n/a
€41.40
0%
16.63%€52.03€27.87€44.529
Jun ’25n/a
€41.50
0%
17.00%€51.50€27.59€43.348
€50.55
Fair Value
2.6% undervalued intrinsic discount
5
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/08 19:24
End of Day Share Price 2025/12/08 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Akero Therapeutics, Inc. is covered by 10 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason ZemanskyBofA Global Research
Alexandria HammondBofA Global Research
Citi ResearchCitigroup Inc